STOCK TITAN

EFFECTOR THERAPUTCS INC - EFTR STOCK NEWS

Welcome to our dedicated page for EFFECTOR THERAPUTCS news (Ticker: EFTR), a resource for investors and traders seeking the latest updates and insights on EFFECTOR THERAPUTCS stock.

eFFECTOR Therapeutics, Inc., headquartered in San Diego, is a cutting-edge biotechnology company that focuses on developing a novel class of oncology drugs known as selective translation regulator inhibitors (STRIs). The company's mission is to advance cancer treatment by targeting key molecular mechanisms that drive the disease.

eFFECTOR's flagship product, zotatifin, is currently under Phase 1/2 clinical trials for ER+/HER2- metastatic breast cancer. Recently, zotatifin received Fast Track designation from the U.S. FDA in combination with fulvestrant and abemaciclib, underscoring its potential in treating advanced or metastatic breast cancer. In these trials, zotatifin showed promising results with a 26% partial response rate in heavily pretreated patients.

Another key product in eFFECTOR's pipeline is tomivosertib, an MNK inhibitor being evaluated in a Phase 2b trial for metastatic non-small cell lung cancer (NSCLC). The company's research extends to other biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC.

eFFECTOR is also collaborating globally with Pfizer to develop inhibitors targeting eIF4E, further enhancing its research capabilities and clinical development. This partnership aims to streamline the translation of groundbreaking findings into viable treatments for cancer patients.

Financially, eFFECTOR continues to strengthen its position through strategic offerings, raising approximately $15 million in recent direct offerings. This capital helps advance their research projects and maintain a robust developmental pipeline.

Additionally, eFFECTOR announced a reverse stock split aimed at regaining compliance with Nasdaq's minimum bid price requirements, effective January 12, 2024. This move is intended to better position the company within the stock market, ensuring long-term growth and stability.

Stay updated with eFFECTOR's latest developments as they continue to innovate in the field of oncology, pushing the boundaries of cancer treatment.

Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) announced it will wind down operations and explore strategic alternatives for its development programs. The decision, made during a special board meeting, involves terminating employees and preparing for delisting from Nasdaq. The company acknowledges non-compliance with Nasdaq's listing requirements and plans to request voluntary delisting soon. Craig R. Jalbert, an expert in distressed businesses, has been appointed as CEO, President, Treasurer, Secretary, and sole board member to oversee the wind-down process. Jalbert has extensive experience managing companies in their wind-down phases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-75.81%
Tags
none
-
Rhea-AI Summary

eFFECTOR Therapeutics announced a collaboration with the Dana-Farber Cancer Institute for an investigator-sponsored Phase 2 trial. The trial will evaluate zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer. Dr. Panagiotis Konstantinopoulos, Director of Translational Research at DFCI, will oversee the study. The trial aims to address the resistance seen in current treatments by targeting eIF4A, thereby improving outcomes. Concurrently, eFFECTOR is progressing zotatifin in ER+ metastatic breast cancer, expecting Phase 2 dosing results in late 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
-
Rhea-AI Summary

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) reported financial results for Q1 2024 and provided a corporate update. The company raised $15.0 million in gross proceeds extending cash runway. The focus is on the zotatifin program and advancing it efficiently. The ZFA triplet is showing promising results with 7.4 month mPFS in heavily pre-treated patients. The KICKSTART trial results were disappointing, leading to a shift in focus. The company's cash position is strong, with cash expected to last until Q1 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) will present at the Stifel Virtual Oncology Forum on April 16th, discussing their selective translation regulator inhibitors for cancer treatment. The webcast will be live on their website with a 90-day replay option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.45%
Tags
conferences
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (EFTR) announces topline results from the Phase 2 KICKSTART trial for tomivosertib in NSCLC, showing promising PFS results but not meeting statistical significance. The company shifts focus to developing zotatifin for ER+ breast cancer with positive data and plans for upcoming trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-82.03%
Tags
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (EFTR) provided updates on their Phase 2b KICKSTART trial for tomivosertib in NSCLC and zotatifin in ER+ breast cancer. They expect topline data in early April 2024, with positive results potentially leading to Phase 3 trials. The company raised $15.0 million in financing, extending cash runway into Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14th. The company is a leader in the development of selective translation regulator inhibitors for cancer treatment. The presentation will be available via live webcast and replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
conferences
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) has completed a registered direct offering, selling 1,488,834 shares of its common stock and short-term warrants to purchase an additional 1,488,834 shares. The offering generated approximately $15 million in gross proceeds, with H.C. Wainwright & Co. acting as the exclusive placement agent. The Company plans to utilize the funds for general corporate and working capital purposes, including research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (EFTR) has announced a definitive agreement for the purchase and sale of 1,488,834 shares of its common stock and warrants to purchase up to the same number of shares at an offering price of $10.075 per share. The warrants will be exercisable immediately upon issuance, with an exercise price of $9.95 per share. The closing of the offering is expected soon, and the funds raised will be used for general corporate purposes and to support the development of its selective translation regulator inhibitors for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.74%
Tags
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announces a virtual investor R&D Day on January 24, 2024, to review the development progress of tomivosertib and zotatifin, including recently announced interim data from dose escalation and Phase 2 expansion cohorts of zotatifin in ER+ metastatic breast cancer patients. The company also previews anticipated 2024 milestones and topline results from the Phase 2b KICKSTART clinical trial of tomivosertib combined with pembrolizumab for the treatment of frontline NSCLC in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.87%
Tags
conferences

FAQ

What is the current stock price of EFFECTOR THERAPUTCS (EFTR)?

The current stock price of EFFECTOR THERAPUTCS (EFTR) is $0.03245 as of October 15, 2024.

What is the market cap of EFFECTOR THERAPUTCS (EFTR)?

The market cap of EFFECTOR THERAPUTCS (EFTR) is approximately 611.6K.

What is eFFECTOR Therapeutics' primary focus?

eFFECTOR Therapeutics focuses on developing selective translation regulator inhibitors (STRIs) for cancer treatment.

What recent achievement did eFFECTOR announce?

The FDA granted Fast Track designation for zotatifin in combination with fulvestrant and abemaciclib for treating ER+/HER2- metastatic breast cancer.

What products are in eFFECTOR's pipeline?

Key products include zotatifin and tomivosertib, targeting various solid tumors and metastatic cancers.

How is eFFECTOR collaborating with other companies?

eFFECTOR has a global collaboration with Pfizer to develop inhibitors targeting eIF4E.

What are the financial highlights of eFFECTOR?

eFFECTOR raised approximately $15 million through a recent direct offering to support its research and development efforts.

What is the significance of the recent reverse stock split?

The reverse stock split aims to regain compliance with Nasdaq's minimum bid price requirements, effective January 12, 2024.

What types of cancer are eFFECTOR's products targeting?

Their products target various solid tumors, including ER+ breast cancer, KRAS-mutant NSCLC, and metastatic non-small cell lung cancer.

What is the potential benefit of zotatifin's Fast Track designation?

It facilitates development and expedited review, potentially bringing the treatment to market faster.

How is eFFECTOR funded for its developments?

Through strategic offerings and collaborations, eFFECTOR continues to secure the financial resources needed for its research.

What are the recent clinical trial results for zotatifin?

In recent trials, zotatifin showed a 26% partial response rate in heavily pretreated patients with ER+/HER2- metastatic breast cancer.

EFFECTOR THERAPUTCS INC

Nasdaq:EFTR

EFTR Rankings

EFTR Stock Data

611.57k
4.70M
2.91%
21.73%
1.95%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOLANA BEACH